Koglin J, Granville D J, Glysing-Jensen T, Mudgett J S, Carthy C M, McManus B M, Russell M E
Cardiovascular Biology Laboratory, Harvard School of Public Health, Boston, Mass. 02115, USA.
Circulation. 1999 Feb 16;99(6):836-42. doi: 10.1161/01.cir.99.6.836.
The mechanisms through which NOS2-mediated pathways regulate graft failure in acute cardiac rejection are ill defined. To determine whether apoptosis promoted by NOS2 may contribute, we used a heterotopic transplant model to study mouse cardiac allografts placed in recipients with targeted gene deletion of NOS2.
Using 5 different indexes of apoptosis, we showed that mouse cardiac allografts placed in NOS2 -/- recipients (n=7) had reduced apoptotic activity compared with those in NOS2 +/+ controls (n=8). There were significantly fewer TUNEL-positive nuclei per high-powered field (P<0.01), less DNA fragmentation (antinucleosome ELISA; P<0.05), lower corrected transcript levels for caspase-1 and -3 (32P reverse transcriptase-polymerase chain reaction; P<0.01), and reduced caspase-3 activity (cleavage of DEVD-pNA [P<0.001] and poly [ADP-ribose] polymerase) in grafts from NOS2 -/- recipients. This concordant reduction in apoptotic indexes paralleled the improved histological outcome of grafts transplanted into NOS2 -/- recipients (assessed as rejection scores; P=0.012). To identify pathways controlled by NOS2, we compared intragraft transcript levels of potential triggers and regulators. Whereas Fas ligand/Fas and tumor necrosis factor (TNF)-alpha/TNF receptor-1 levels were not altered by NOS2 deficiency, transcript levels for p53 were significantly lower in grafts from NOS2 -/- recipients, coinciding with a significant increase in the antiapoptotic Bcl-2/Bax balance and decrease in Bcl-Xl levels.
Using NOS2 knockout mice, we demonstrated that NOS2-mediated pathways can promote acute rejection, at least in part, by inducing apoptotic cell death. When NOS2 is present, p53 might control NOS2-mediated apoptosis by stimulating Bax and repressing Bcl-2 and Bcl-Xl expression, which may activate the cell death program in the rejecting heart.
一氧化氮合酶2(NOS2)介导的通路调节急性心脏排斥反应中移植物衰竭的机制尚不明确。为了确定NOS2促进的细胞凋亡是否起作用,我们使用异位移植模型研究了将小鼠心脏异体移植物植入NOS2基因敲除的受体体内的情况。
使用5种不同的细胞凋亡指标,我们发现,与野生型(NOS2 +/+)对照受体(n = 8)体内的小鼠心脏异体移植物相比,植入NOS2基因敲除(NOS2 -/-)受体(n = 7)体内的移植物凋亡活性降低。在高倍视野下,NOS2 -/-受体体内移植物的TUNEL阳性细胞核明显更少(P < 0.01),DNA片段化程度更低(抗核小体ELISA;P < 0.05),半胱天冬酶-1和-3的校正转录水平更低(32P逆转录聚合酶链反应;P < 0.01),且半胱天冬酶-3活性降低(DEVD-pNA裂解[P < 0.001]和聚[ADP-核糖]聚合酶)。这些凋亡指标的一致降低与植入NOS2 -/-受体体内移植物改善的组织学结果相平行(评估为排斥评分;P = 0.012)。为了确定由NOS2控制的通路,我们比较了移植物内潜在触发因素和调节因子的转录水平。虽然NOS2缺陷未改变Fas配体/Fas和肿瘤坏死因子(TNF)-α/TNF受体-1的水平,但NOS2 -/-受体体内移植物中p53的转录水平显著更低,同时抗凋亡的Bcl-2/Bax平衡显著增加,Bcl-Xl水平降低。
使用NOS2基因敲除小鼠,我们证明NOS2介导的通路至少部分可通过诱导凋亡性细胞死亡来促进急性排斥反应。当存在NOS2时,p53可能通过刺激Bax并抑制Bcl-2和Bcl-Xl的表达来控制NOS2介导的细胞凋亡,这可能激活排斥反应心脏中的细胞死亡程序。